Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

RCT (n=1118) did not meet its primary end points of improved overall survival (OS) with durvalumab vs chemotherapy or improved OS or progression-free survival with durvalumab plus tremelimumab vs chemotherapy in patients with ≥25% of tumor cells expressing PD-L1.


JAMA Oncology